Imugene (AXS: IMU) Commences Phase 1b/2 Gastric Cancer Study, Receives Approvals to Initiate Clinical Trial & Secures Further Intellectual Property

Imugene Limited (ASX: IMU), an immunoncology company is pleased to release its Appendix 4C for the quarter ended 30th June, 2017.

KEY TAKEAWAYS:

  • Commenced the Phase 1b/2 gastric cancer study for HER-Vaxx
  • Received full and final country regulatory approvals to initiate clinical trial;
  • Commenced patient recruitment in all 8 clinical sites in Thailand, Taiwan and Hong Kong
  • Secured further intellectual property for HER-Vaxx
  • Completed further development of the next generation of mimotope targets and pipeline
  • Commenced in vivo testing of arginine modulator in animal models of cancer

Imugene (ASX:IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.

More Information

Request Information